Aurobindo Pharma Ltd (AUROPHARMA) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-1.50%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 16.4%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 10.1%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹1,763.54

200-Day DMA ● Overlay

₹1,635.61

14-Day RSI ● Overlay

46.8 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹96,798 Cr

Large cap

Stock P/E (TTM) Valuation

25.7x

Price / EPS

Book Value (₹) Assets

₹652.0

P/B: 2.6x

ROE (%) Quality

10.1%

Net Profit / Equity

ROCE (%) Efficiency

12.9%

EBIT / Capital

Dividend Yield Yield

0.24%

Face Value: ₹10

Debt / Equity Solvency

0.21x

Manageable

EPS (TTM) Per Share

₹65.31

Trailing 12M

OPM (%) Spread

20.0%

EBITDA Margin

Free Cash Flow Cash

₹2,468 Cr

CFO - Capex

About Aurobindo Pharma Ltd

Aurobindo Pharma Ltd (AUROPHARMA) is an Indian publicly listed company operating in the Healthcare & Pharma sector.

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 14.4% × Turnover: 0.85x × Leverage: 1.21x = ROE: 10.1%

✓ Company Strengths (Pros)

• Company has maintained a healthy low debt-to-equity ratio of 0.21.
• TickerPulse fundamental algorithm rates overall quality at 80/100.

⚠ Key Considerations & Risks (Cons)

• Valuation is sensitive to broader macroeconomic and sectoral interest rate cycles.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹34,935 Cr

Latest PAT

₹3,711 Cr

EPS (TTM)

₹65.31

OPM %

20.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹8,122 Cr	₹8,472 Cr	₹8,908 Cr	₹9,258 Cr
Operating Profit (EBITDA)	₹1,576 Cr	₹1,677 Cr	₹1,800 Cr	₹1,907 Cr
OPM %	19.4%	19.8%	20.2%	20.6%
Interest Expense	₹126.06 Cr	₹134.19 Cr	₹143.96 Cr	₹152.57 Cr
Depreciation	₹189.09 Cr	₹201.29 Cr	₹215.94 Cr	₹228.85 Cr
Profit before Tax (PBT)	₹1,261 Cr	₹1,342 Cr	₹1,440 Cr	₹1,526 Cr
Net Profit (PAT)	₹945.44 Cr	₹1,006 Cr	₹1,080 Cr	₹1,144 Cr
EPS in ₹	₹16.55	₹17.26	₹18.15	₹18.87

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹13,275 Cr	₹15,022 Cr	₹17,118 Cr	₹19,564 Cr	₹22,358 Cr	₹24,105 Cr	₹25,852 Cr	₹30,044 Cr	₹32,490 Cr	₹34,236 Cr	₹34,935 Cr	₹36,332 Cr
Expenses	₹10,859 Cr	₹12,198 Cr	₹13,831 Cr	₹15,612 Cr	₹17,775 Cr	₹19,429 Cr	₹20,371 Cr	₹23,795 Cr	₹26,122 Cr	₹27,389 Cr	₹27,843 Cr	₹28,884 Cr
Operating Profit	₹2,416 Cr	₹2,824 Cr	₹3,287 Cr	₹3,952 Cr	₹4,583 Cr	₹4,676 Cr	₹5,481 Cr	₹6,249 Cr	₹6,368 Cr	₹6,847 Cr	₹7,092 Cr	₹7,448 Cr
OPM %	18.2%	18.8%	19.2%	20.2%	20.5%	19.4%	21.2%	20.8%	19.6%	20%	20.3%	20.5%
Interest	₹169.13 Cr	₹197.69 Cr	₹230.07 Cr	₹276.63 Cr	₹320.84 Cr	₹327.35 Cr	₹383.64 Cr	₹437.44 Cr	₹445.76 Cr	₹479.31 Cr	₹496.43 Cr	₹521.37 Cr
Depreciation	₹289.93 Cr	₹338.90 Cr	₹394.40 Cr	₹474.22 Cr	₹550.02 Cr	₹561.17 Cr	₹657.67 Cr	₹749.90 Cr	₹764.15 Cr	₹821.67 Cr	₹851.02 Cr	₹893.78 Cr
Profit before Tax	₹2,174 Cr	₹2,542 Cr	₹2,958 Cr	₹3,557 Cr	₹4,125 Cr	₹4,209 Cr	₹4,933 Cr	₹5,624 Cr	₹5,731 Cr	₹6,163 Cr	₹6,383 Cr	₹6,703 Cr
Net Profit	₹1,631 Cr	₹1,906 Cr	₹2,219 Cr	₹2,668 Cr	₹3,094 Cr	₹3,157 Cr	₹3,699 Cr	₹4,218 Cr	₹4,298 Cr	₹4,622 Cr	₹4,787 Cr	₹5,027 Cr
EPS in Rs	27.05	30.61	34.88	39.87	45.56	49.12	52.68	61.23	66.21	69.77	71.19	74.04

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹1,016 Cr	₹1,162 Cr	₹1,365 Cr	₹1,597 Cr	₹1,829 Cr	₹2,033 Cr	₹2,207 Cr	₹2,439 Cr	₹2,643 Cr	₹2,817 Cr	₹2,904 Cr
Reserves & Surplus	₹13,213 Cr	₹15,100 Cr	₹17,743 Cr	₹20,763 Cr	₹23,783 Cr	₹26,426 Cr	₹28,691 Cr	₹31,711 Cr	₹34,354 Cr	₹36,619 Cr	₹37,751 Cr
Borrowings (Debt)	₹2,775 Cr	₹3,171 Cr	₹3,726 Cr	₹4,360 Cr	₹4,994 Cr	₹5,549 Cr	₹6,025 Cr	₹6,659 Cr	₹7,214 Cr	₹7,690 Cr	₹7,928 Cr
Total Liabilities	₹25,409 Cr	₹29,039 Cr	₹34,121 Cr	₹39,929 Cr	₹45,737 Cr	₹50,819 Cr	₹55,175 Cr	₹60,983 Cr	₹66,065 Cr	₹70,421 Cr	₹72,599 Cr
Fixed Assets	₹12,197 Cr	₹13,939 Cr	₹16,378 Cr	₹19,166 Cr	₹21,954 Cr	₹24,393 Cr	₹26,484 Cr	₹29,272 Cr	₹31,711 Cr	₹33,802 Cr	₹34,847 Cr
Total Assets	₹25,409 Cr	₹29,039 Cr	₹34,121 Cr	₹39,929 Cr	₹45,737 Cr	₹50,819 Cr	₹55,175 Cr	₹60,983 Cr	₹66,065 Cr	₹70,421 Cr	₹72,599 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹2,265 Cr	₹2,580 Cr	₹3,020 Cr	₹3,398 Cr	₹3,901 Cr	₹4,278 Cr	₹4,719 Cr	₹5,348 Cr	₹5,789 Cr	₹6,166 Cr	₹6,292 Cr
Cash from Investing (CFI)	-₹1,404 Cr	-₹1,599 Cr	-₹1,872 Cr	-₹2,107 Cr	-₹2,419 Cr	-₹2,653 Cr	-₹2,926 Cr	-₹3,316 Cr	-₹3,589 Cr	-₹3,823 Cr	-₹3,901 Cr
Cash from Financing (CFF)	-₹724.82 Cr	-₹825.49 Cr	-₹966.43 Cr	-₹1,087 Cr	-₹1,248 Cr	-₹1,369 Cr	-₹1,510 Cr	-₹1,711 Cr	-₹1,852 Cr	-₹1,973 Cr	-₹2,013 Cr
Free Cash Flow (FCF)	₹1,142 Cr	₹1,300 Cr	₹1,522 Cr	₹1,712 Cr	₹1,966 Cr	₹2,156 Cr	₹2,378 Cr	₹2,695 Cr	₹2,917 Cr	₹3,108 Cr	₹3,171 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	10.9%	11.3%	11.7%	12.1%	12.5%	12.9%	13.3%	13.7%	14.1%	14.5%	14.9%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹997.46 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹1,827.50

DCF Fair Value

₹997.46

Graham Number

₹978.82

Margin of Safety

-45.9%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹997.46

Premium / Overvalued (Margin: -45.9%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹971	₹962	₹953	₹945
10%	₹989	₹980	₹971	₹962
12%	₹1,007	₹997	₹988	₹980
14%	₹1,025	₹1,015	₹1,006	₹997

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹997	Fairly Valued
Benjamin Graham Number	₹979	Market Priced
Historical Sector P/E	₹1,437	Premium
EV / EBITDA Multiplier	₹1,919	In-Line
Free Cash Flow Yield Model	₹1,791	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 8/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

8 / 9 Pass

Altman Z-Score

5.35 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.21x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 20.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

51.88%

FIIs (Foreign)

16.38%

DIIs (Domestic)

25.05%

Government

0.15%

Public / Retail

6.63%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	52.36%	52.24%	52.12%	52.00%	51.88%	51.76%	51.64%	51.52%
• Promoter & Promoter Group Family Trusts	24.90%	24.90%	24.90%	24.90%	24.90%	24.90%	24.90%	24.90%
• Operating Holding Companies & LLPs	19.71%	19.71%	19.71%	19.71%	19.71%	19.71%	19.71%	19.71%
• Key Executive Promoters (Individual)	7.26%	7.26%	7.26%	7.26%	7.26%	7.26%	7.26%	7.26%
+ FIIs (Foreign Portfolio)	16.09%	16.16%	16.24%	16.31%	16.38%	16.45%	16.52%	16.60%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	24.86%	24.91%	24.95%	25.00%	25.05%	25.10%	25.15%	25.19%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	6.54%	6.54%	6.54%	6.54%	6.54%	6.54%	6.54%	6.54%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

AUROPHARMA Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

AUROPHARMA Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

AUROPHARMA Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹2,339.20

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹2,046.80

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 26x P/E.

🐻 Bear Case (15%) -12.0%

₹1,608.20

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 21:02 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ Aurobindo Pharma Ltd (AUROPHARMA)	Target Stock	₹1,827.50	-1.50%	25.7x	10.1%	12.9%	0.21	₹96,798 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	21:02:41 IST	✓ Live Sync
Financial Statements (10Y)	Aurobindo Pharma Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

Aurobindo Pharma Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About Aurobindo Pharma Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title